Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 6/20 | 0.48 |
| ▸ | CA1 | P00915 | 6/20 | 0.48 |
| ▸ | CA2 | P00918 | 6/20 | 0.48 |
| ▸ | CA9 | Q16790 | 6/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | ITK | Q08881 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20102815 | 1.00 | CA12 (0.48) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL29948350 | 1.00 | CA12 (0.48) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL20102825 | 1.00 | CA12 (0.48) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL25457307 | 0.95 | CA12 (0.46) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL30444087 | 0.90 | EGFR (0.44) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL21549514 | 0.90 | EGFR (0.44) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL25815595 | 0.88 | EGFR (0.51) | CA12CA1CA2CA9AAK1 | |
| SCHEMBL31270840 | 0.86 | CA12 (0.51) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL21326225 | 0.83 | ALDH1A1 (0.43) | ALDH1A1CYP1A2HSP90AA1MAPTCYP2C9 | |
| SCHEMBL20214525 | 0.83 | ALDH1A1 (0.43) | ALDH1A1CYP1A2HSP90AA1MAPTCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570654-B2 | Nanoluc suicide substrates | PROMEGA CORPORATION (US) | 2026-03-10 | — | — | US | disclosed |
| US-20230382908-A1 | NANOLUC SUICIDE SUBSTRATES | PROMEGA CORPORATION | 2023-11-30 | — | — | US | disclosed |
| US-11655247-B2 | Nanoluc suicide substrates | PROMEGA CORPORATION (US) | 2023-05-23 | — | — | US | disclosed |
| EP-4144738-A1 | COELENTERAZINE ANALOGUES TETHERED TO ENERGY ACCEPTORS | Promega Corporation (US) | 2023-03-08 | — | — | EP | disclosed |
| EP-3535270-B1 | COELENTERAZINE ANALOGUES TETHERED TO ENERGY ACCEPTORS | PROMEGA CORP (US) | 2022-07-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382908-A1 | NANOLUC SUICIDE SUBSTRATES | XIAP, NLN, BAD | CA12 4710/4885CA1 3730/4885CA2 4512/4885 |
| US-11655247-B2 | Nanoluc suicide substrates | XIAP, NLN, BAD | CA12 4710/4885CA1 3730/4885CA2 4512/4885 |
| US-12570654-B2 | Nanoluc suicide substrates | NR3C1, LUC7L2, L3MBTL1 | CA12 3938/4885CA1 1692/4885CA2 3535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.